Company: IMRX
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001790340-25-000053
Chunk: 38

Company: Immuneering Corp
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 38
---
ention Period, to provide added incentive to retain and motivate the holders of the Eligible Options, including Mr. Bookman, to continue to work in the best interests of the Company and its stockholders without incurring the stock dilution resulting from significant additional equity grants or significant additional cash expenditures resulting from additional cash compensation. The exercise price that served as the threshold for options that qualify as Eligible Options, which is $3.01 per share, was selected because it was approximately two times the closing trading price of our Class A common stock on the Nasdaq Global Market on the Repricing Effective Date and not below the lowest exercise price of options granted under our equity incentive plan that preceded the 2021 Plan, which were not eligible for the repricing.

#### Other elements of compensation
Retirement plans

We currently maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy certain eligibility requirements. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees. The 401(k) plan allows eligible employees to defer a portion of their compensation, within prescribed limits, on a pre-tax basis through contributions to the 401(k) plan. For 2024, we matched contributions made by participants in the 401(k) plan up to four percent of a participant’s eligible compensation. We believe that providing a vehicle for tax-deferred retirement savings though our 401(k) plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies.

Health and welfare plans

All of our full-time employees, including our named executive officers, are eligible to participate in our health and welfare plans on the same terms.

<div align='center'>26</div>

TABLE OF CONTENTS

#### Outstanding Equity Awards at 2024 Fiscal Year-End
| Name                       |     | Vesting Start 
 Date          |     | Number of   
 securities  
 underlying  
 unexercised 
 options (#) 
 exercisable |     |         |    |     | Number of     
 securities    
 underlying    
 unexercised   
 options (#)   
 unexercisable |     |         |    |     | Option    
 exercise  
 price ($) |       |     | Option     
 expiration 
 date       |     |            |
| Benjamin J. Zeskind, Ph.D. |     | 9/20/2019     |     |             |